Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer after local therapy of isolated brain progression

Next Previous
X
Search
Trial Profile

Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer after local therapy of isolated brain progression

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary) ; Anastrozole; Fulvestrant; Letrozole
  • Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms InTTercePT; UCBG/GINECO study

    • Most Recent Events

    • 29 Mar 2024 Last checked against European Clinical Trials Database.
    • 21 Sep 2023 Planned End Date changed from 30 Jun 2025 to 30 Mar 2026.
    • 21 Sep 2023 Planned primary completion date changed from 30 Dec 2024 to 30 Mar 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top